Homologous recombination deficiency positive advanced ovarian cancer

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
4 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody (angiogenesis) 1 substance
Platinum compound 1 substance
PARP inhibitor 1 substance
Taxane 1 substance
Phase II: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase II

1 trial
  • Tesaro Inc. Commercial
    BEVACIZUMAB; CARBOPLATIN; NIRAPARIB TOSILATE MONOHYDRATE; PACLITAXEL
    2023-505097-16-00 1 country 2022 n=15 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Tesaro Inc. Commercial 1 Phase II 0
New trials by year
2022
1
← All indication landscapes